|
1
|
Field JK and Duffy SW: Lung cancer
screening: The way forward. Br J Cancer. 99:557–562. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramalingam SS, Maitland ML, Frankel P,
Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I,
Vokes EE, Gandara DR and Belani CP: Carboplatin and Paclitaxel in
combination with either vorinostat or placebo for first-line
therapy of advanced non-small-cell lung cancer. J Clin Oncol.
28:56–62. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Joshi M, Liu X and Belani CP: Taxanes,
past, present, and future impact on non-small cell lung cancer.
Anticancer Drugs. 25:571–583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xirodimas DP: Novel substrates and
functions for the ubiquitin-like molecule NEDD8. Biochem Soc Trans.
36:802–806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng N, Schulman BA, Song L, Miller JJ,
Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al:
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase
complex. Nature. 416:703–709. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jia L and Sun Y: SCF E3 ubiquitin ligases
as anticancer targets. Curr Cancer Drug Targets. 11:347–356. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brown JS and Jackson SP: Ubiquitylation,
neddylation and the DNA damage response. Open Biol. 5:1500182015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sarantopoulos J, Shapiro GI, Cohen RB,
Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD,
Faessel HM, et al: Phase I study of the investigational
NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/mlN4924) in
patients with advanced solid tumors. Clin Cancer Res. 22:847–857.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nawrocki ST, Griffin P, Kelly KR and Carew
JS: MLN4924: A novel first-in-class inhibitor of NEDD8-activating
enzyme for cancer therapy. Expert Opin Investig Drugs.
21:1563–1573. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin JJ, Milhollen MA, Smith PG, Narayanan
U and Dutta A: NEDD8-targeting drug MLN4924 elicits DNA
rereplication by stabilizing Cdt1 in S phase, triggering checkpoint
activation, apoptosis, and senescence in cancer cells. Cancer Res.
70:10310–10320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mackintosh C, Garcia-Dominguez DJ, Ordóñez
JL, Ginel-Picardo A, Smith PG, Sacristán MP and de Álava E: WEE1
accumulation and deregulation of S-phase proteins mediate MLN4924
potent inhibitory effect on Ewing sarcoma cells. Oncogene.
32:1441–1451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blank JL, Liu XJ, Cosmopoulos K, Bouck DC,
Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, et al:
Novel DNA damage checkpoints mediating cell death induced by the
NEDD8-activating enzyme inhibitor MLN4924. Cancer Res. 73:225–234.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soucy TA, Smith PG, Milhollen MA, Berger
AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP,
Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a
new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jazaeri AA, Shibata E, Park J, Bryant JL,
Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ and
Dutta A: Overcoming platinum resistance in preclinical models of
ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer
Ther. 12:1958–1967. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nawrocki ST, Kelly KR, Smith PG, Espitia
CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M,
Berger A and Carew JS: Disrupting protein NEDDylation with MLN4924
is a novel strategy to target cisplatin resistance in ovarian
cancer. Clin Cancer Res. 19:3577–3590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lv K, Liu L, Wang L, Yu J, Liu X, Cheng Y,
Dong M, Teng R, Wu L, Fu P, et al: Lin28 mediates paclitaxel
resistance by modulating p21, Rb and Let-7a miRNA in breast cancer
cells. PLoS One. 7:e400082012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim EH, Min HY, Chung HJ, Song J, Park HJ,
Kim S and Lee SK: Anti-proliferative activity and suppression of
P-glycoprotein by (−)-antofine, a natural phenanthroindolizidine
alkaloid, in paclitaxel-resistant human lung cancer cells. Food
Chem Toxicol. 50:1060–1065. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao
Y, Piao Y, Liu J, Cheng W, Bi X, et al: Encorafenib (LGX818), a
potent BRAF inhibitor, induces senescence accompanied by autophagy
in BRAFV600E melanoma cells. Cancer Lett. 370:332–344. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu L, Sun S, Wang T, Li Y, Jiang K, Lin G,
Ma Y, Barr MP, Song F, Zhang G and Meng S: Oncolytic newcastle
disease virus triggers cell death of lung cancer spheroids and is
enhanced by pharmacological inhibition of autophagy. Am J Cancer
Res. 5:3612–3623. 2015.PubMed/NCBI
|
|
21
|
Li H, Tan M, Jia L, Wei D, Zhao Y, Chen G,
Xu J, Zhao L, Thomas D, Beer DG and Sun Y: Inactivation of SAG/RBX2
E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.
J Clin Invest. 124:835–846. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L, Wang M, Yu G, Chen P, Li H, Wei D,
Zhu J, Xie L, Jia H, Shi J, et al: Overactivated neddylation
pathway as a therapeutic target in lung cancer. J Natl Cancer Inst.
106:dju0832014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D,
Pan Y, Ding C, Qian J, Wu L, et al: The Nedd8-activating enzyme
inhibitor MLN4924 induces autophagy and apoptosis to suppress liver
cancer cell growth. Cancer Res. 72:3360–3371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gu Y, Kaufman JL, Bernal L, Torre C,
Matulis SM, Harvey RD, Chen J, Sun SY, Boise LH and Lonial S:
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via
upregulation of REDD1 in human myeloma cells. Blood. 123:3269–3276.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Loessner D, Flegg JA, Byrne HM, Clements
JA and Hutmacher DW: Growth of confined cancer spheroids: A
combined experimental and mathematical modelling approach. Integr
Biol (Camb). 5:597–605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pampaloni F, Reynaud EG and Stelzer EH:
The third dimension bridges the gap between cell culture and live
tissue. Nat Rev Mol Cell Biol. 8:839–845. 2007. View Article : Google Scholar : PubMed/NCBI
|
